{"DataElement":{"publicId":"13489566","version":"1","preferredName":"Lung Carcinoma Tissue Sample Primary Pathologic Group Category","preferredDefinition":"The response indicating the higher level pathologic category attributed to the lung tissue sample.","longName":"MajorPathologicGroup","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"13486821","version":"1","preferredName":"Tissue Sample Primary Pathologic Group","preferredDefinition":"A piece of tissue removed from an organism for examination, analysis, or propagation.:Occurring first in time or sequence; original; of greatest rank or importance or value._Caused by or altered by or manifesting disease or pathology._Any number of entities (members) considered as a unit.","longName":"2480187v1.00:13486820v1.00","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2480187","version":"1","preferredName":"Tissue Sample","preferredDefinition":"No value exists.","longName":"C19697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tissue Sample","conceptCode":"C19697","definition":"A piece of tissue removed from an organism for examination, analysis, or propagation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"12E6A5F5-D3AD-189F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-05-03","modifiedBy":"COOPERM","dateModified":"2019-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"13486820","version":"1","preferredName":"Primary Pathologic Group","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value._Caused by or altered by or manifesting disease or pathology._Any number of entities (members) considered as a unit.","longName":"C25251:C25610:C43359","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Group","conceptCode":"C43359","definition":"Any number of entities (members) considered as a unit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FACEED1F-815F-2562-E053-731AD00AB08C","latestVersionIndicator":"Yes","beginDate":"2023-05-03","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-03","modifiedBy":"GDEEN","dateModified":"2023-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCG:Center for Cancer Genomics","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FACEED1F-8160-2562-E053-731AD00AB08C","latestVersionIndicator":"Yes","beginDate":"2023-05-03","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-03","modifiedBy":"GDEEN","dateModified":"2023-05-15","changeDescription":null,"administrativeNotes":"05.15.23_Curated to support MILD_ghd","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13474510","version":"1","preferredName":"Lung Carcinoma Primary Pathologic Category","preferredDefinition":"A grouping of items based on some commonality or by user defined characteristics._Occurring first in time or sequence; original; of greatest rank or importance or value._Caused by or altered by or manifesting disease or pathology.","longName":"13474510v1.00","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Adenocarcinoma","valueDescription":null,"ValueMeaning":{"publicId":"2831117","version":"1","preferredName":"Adenocarcinoma","longName":"2831117","preferredDefinition":"carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D06-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FAAA4F72-89CD-2385-E053-731AD00ABFBB","beginDate":"2023-05-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-01","modifiedBy":"GDEEN","dateModified":"2023-05-01","deletedIndicator":"No"},{"value":"Squamous cancer","valueDescription":null,"ValueMeaning":{"publicId":"4264988","version":"1","preferredName":"Squamous Cell Carcinoma","longName":"4264988","preferredDefinition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3EBF-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FAAA5867-BAB8-24B7-E053-731AD00A5A03","beginDate":"2023-05-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-01","modifiedBy":"GDEEN","dateModified":"2023-05-01","deletedIndicator":"No"},{"value":"Large cell carcinoma","valueDescription":null,"ValueMeaning":{"publicId":"4264919","version":"1","preferredName":"Large Cell Carcinoma","longName":"4264919","preferredDefinition":"A malignant epithelial neoplasm composed of large, atypical cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEA17-6068-3E0B-E040-BB89AD4363B5","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FAAA5867-BAB9-24B7-E053-731AD00A5A03","beginDate":"2023-05-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-01","modifiedBy":"GDEEN","dateModified":"2023-05-01","deletedIndicator":"No"},{"value":"Small cell carcinoma","valueDescription":null,"ValueMeaning":{"publicId":"2567204","version":"1","preferredName":"Small cell carcinoma","longName":"2567204","preferredDefinition":"A neuroendocrine carcinoma composed of small malignant cells which are often said to resemble \"oat cells\" under the microscope.  Small cell carcinoma most often affects the lungs.  Clinically, this is often a rapidly growing cancer that spreads to distant sites early.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Cell Neuroendocrine Carcinoma","conceptCode":"C3915","definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant small cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D391-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"REEVESD","dateModified":"2016-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FAAA5867-BABA-24B7-E053-731AD00A5A03","beginDate":"2023-05-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-01","modifiedBy":"GDEEN","dateModified":"2023-05-01","deletedIndicator":"No"},{"value":"Typical or atypical carcinoid","valueDescription":null,"ValueMeaning":{"publicId":"2956072","version":"1","preferredName":"Carcinoid Tumor","longName":"2956072","preferredDefinition":"Carcinoid tumor, also known as well differentiated endocrine neoplasm, is a slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis.  The tumor may show a variety of patterns, such as solid, trabecular, and acinar.  Electron microscopy shows small secretory granules.  Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity.  Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen.  Such cases may have an aggressive clinical course.  Gastrointestinal tract and lung are common sites of involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoid Tumor","conceptCode":"C2915","definition":"A slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis.  The tumor may show a variety of patterns, such as solid, trabecular, and acinar.  Electron microscopy shows small secretory granules.  Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity.  Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen.  Such cases may have an aggressive clinical course.  Gastrointestinal tract and lung are common sites of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76EBECE2-B719-A0E2-E040-BB89AD435984","latestVersionIndicator":"Yes","beginDate":"2009-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FAAA5867-BABB-24B7-E053-731AD00A5A03","beginDate":"2023-05-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-01","modifiedBy":"GDEEN","dateModified":"2023-05-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13490137","version":"1","preferredName":"Lung Carcinoma Primary Pathologic Category","preferredDefinition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors._Occurring first in time or sequence; original; of greatest rank or importance or value._Caused by or altered by or manifesting disease or pathology._A grouping of items based on some commonality or by user defined characteristics.","longName":"13490137v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAD03170-682F-59EB-E053-731AD00A9CA9","latestVersionIndicator":"Yes","beginDate":"2023-05-03","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-03","modifiedBy":"GDEEN","dateModified":"2023-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAA94BBD-9235-7394-E053-731AD00A6872","latestVersionIndicator":"Yes","beginDate":"2023-05-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-01","modifiedBy":"GDEEN","dateModified":"2023-05-15","changeDescription":null,"administrativeNotes":"05.15.23_Curated to support MILD_ghd","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3533741","version":"1","longName":"NCORP (NCI Community Oncology Research Program","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3533742","version":"1","longName":"Screening and Accrual Log","context":"NCIP"}]},{"publicId":"6705584","version":"1","longName":"CCG PTCL (Center for Cancer Genomics - Peripheral T Cell Lymphoma)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"13461199","version":"1","longName":"MILD","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Major pathologic group","url":null,"context":"NCIP"}],"origin":"CCG:Center for Cancer Genomics","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FACF0C0E-BADB-2A31-E053-731AD00A86D2","latestVersionIndicator":"Yes","beginDate":"2023-05-03","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-03","modifiedBy":"GDEEN","dateModified":"2023-05-15","changeDescription":null,"administrativeNotes":"05.15.23_Curated to support MILD_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}